Can you provide more details on apotex's ruxolitinib generic us filing?

When does Apotex plan to launch its ruxolitinib generic?

Apotex has filed an ANDA with the FDA for a generic version of ruxolitinib, the active ingredient in Jakafi. The company expects to launch once patent and regulatory barriers fall, but specific launch dates remain undisclosed publicly.

How long does ruxolitinib patent protection last?

Ruxolitinib itself has multiple patents listed in the FDA Orange Book covering composition, formulation, and methods of use. The latest listed patent expires in 2030, but Apotex’s filing suggests it challenges at least one key patent through a Paragraph IV certification.

Why are companies like Apotex challenging this patent?

Paragraph IV certifications allow generic makers to claim that patents are invalid or not infringed. Companies pursue these certifications to gain 180-day exclusivity as the first filer, which can deliver substantial revenue before full patent expiry. Incyte has defended its patents vigorously in past litigation.

What are existing ruxolitinib competitors?

Currently, no generic ruxolitinib is approved in the US. Incyte’s branded product, Jakafi, holds the sole market position. Other manufacturers have filed similar ANDAs, including Hetero and Sun Pharma, but their status remains confidential under FDA rules.

When does Jakafi exclusivity expire?

Regulatory exclusivity tied to new chemical entity status expired in 2016. Data exclusivity and remaining method-of-use patents continue through 2030. The combination of patents and litigation will likely determine the actual launch window for generics.

Can biosimilars enter before patent expiry?

Ruxolitinib is a small-molecule drug, not a biologic, therefore biosimilars are unavailable. Generic small-molecule versions of ruxolitinib can enter once patents are resolved through litigation or settlement.